Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) Short Interest Down 39.3% in June

Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA) was the recipient of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 191,896 shares, a drop of 39.3% from the May 31st total of 315,885 shares. Based on an average daily trading volume, of 6,417,679 shares, the short-interest ratio is presently 0.0 days. Currently, 1.1% of the company’s shares are sold short.

Institutional Trading of Genenta Science

Several hedge funds have recently bought and sold shares of GNTA. Citadel Advisors LLC bought a new position in Genenta Science in the third quarter valued at approximately $41,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Genenta Science during the fourth quarter worth $536,000. Norges Bank bought a new stake in shares of Genenta Science during the fourth quarter worth $337,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Genenta Science during the fourth quarter worth $26,000. Finally, Alyeska Investment Group L.P. bought a new stake in Genenta Science in the 4th quarter valued at $328,000. 15.13% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings raised Genenta Science from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Genenta Science Price Performance

Shares of NASDAQ GNTA traded down $0.05 during mid-day trading on Wednesday, reaching $1.79. 108,074 shares of the company’s stock were exchanged, compared to its average volume of 1,263,830. Genenta Science has a twelve month low of $0.55 and a twelve month high of $10.00. The company has a current ratio of 14.16, a quick ratio of 14.16 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $1.19 and a 200 day simple moving average of $1.10.

Genenta Science Company Profile

Genenta Science (NASDAQ: GNTA) is a clinical-stage biotechnology company focused on the development of in vivo hematopoietic stem cell (HSC) gene therapies for the treatment of solid tumors. The company’s proprietary platform enables the transplantation of genetically engineered HSCs that home to tumor sites and continuously deliver immunomodulatory agents. By harnessing the patient’s own stem cells, Genenta aims to establish a sustained, localized anti-tumor immune response with the potential to overcome limitations of traditional cytokine or antibody therapies.

Genenta’s lead product candidate, Temferon, consists of autologous HSCs engineered to produce interferon-alpha under the control of a tumor microenvironment–activated promoter.